Clinical Trial Update: A Pharmacokinetic, Tolerability and Safety Study of Icatibant in Children and Adolescents With Hereditary Angioedema [Phase 3]

View source ↗

Summary

Phase 3 pharmacokinetic, tolerability, and safety study of icatibant in children and adolescents with hereditary angioedema has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• ICATIBANT (icatibant)

Snippet

Sponsor: Shire | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: COMPLETED | Results posted: 2019-03-25